Chinese biotech firms brace for profit hit from Trump tariffs, US funding bill

Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.

Efforts to expand sales of high-value products in China and non-US markets would cushion the blow, analysts say.